Tarsus Pharmaceuticals Inc (NAS:TARS)

Q2 2026 Tarsus Pharmaceuticals, Inc. Earnings Call Transcript

Aug 6, 2026 / 12:00 PM GMT

Release Date Price: $65.45 (+6.79%)

Transcript 10-Q8-K

Key Points

Positve

Tarsus Pharmaceuticals Inc (TARS) reported record second-quarter 2026 net product sales of $173.9 million for XDEMVY, representing over 69% year-over-year growth and approximately 20% quarter-over-quarter growth.
The company raised its full-year 2026 product sales guidance to $685 million to $705 million, reflecting strong underlying business momentum and confidence in continued growth.
Tarsus Pharmaceuticals Inc (TARS) announced the acquisition of Alkeus Pharmaceuticals and its lead asset ALK001, a late-stage investigational therapy for Stargardt disease, which has no FDA-approved treatments and represents a significant market opportunity with an estimated 86,000 patients in the US.
ALK001 has demonstrated a favorable long-term tolerability profile in over 400 patients with up to seven years of treatment exposure, and has shown potential to preserve visual function without negatively impacting night vision, dark adaptation, or color vision.
The company's commercial execution for XDEMVY is strengthening, with the number of eye care professionals prescribing at a near-daily cadence doubling over the past year, retreatment rates advancing into the high teens, and unaided patient awareness of Demodex blepharitis climbing to approximately 30%.
Tarsus Pharmaceuticals Inc (TARS) is building a robust retina portfolio with two Phase III assets (IRX-101 and ALK001), creating potential commercial synergies with a concentrated physician base of about 3,500 retina specialists.

Negative

The acquisition of Alkeus Pharmaceuticals carries a substantial upfront cost of $450 million (comprising $270 million in cash and $180 million in stock), plus up to $350 million in potential regulatory and commercial milestones, increasing financial risk.
Top-line results for the pivotal Phase III NorthStar trial of ALK001 are not expected until the second half of 2029, meaning a long wait before potential approval and revenue generation from this significant investment.
Tarsus Pharmaceuticals Inc (TARS) faces intense competition in the Stargardt disease space, notably from a competitor with a head start in Phase III development, which could impact future market share.
The company's increased full-year R&D expense guidance (now $190 million to $210 million, up from $115 million to $135 million) reflects higher spending, and management indicated that incremental costs from new acquisitions could delay profitability by a quarter or two beyond the previously anticipated 2027 timeline.
The company expects normal seasonal slowdowns in the third quarter due to fewer physician office days, which could temper near-term revenue growth despite the raised annual guidance.
The success of the ALK001 program is heavily dependent on the ongoing NorthStar trial, which is enrolling advanced disease patients, while the cleanest efficacy signals from prior studies were seen in pre-symptomatic and early-stage patients, creating uncertainty about the pivotal trial's outcome.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TARS.OQ - Tarsus Pharmaceuticals, Inc.
Q2 2026 Tarsus Pharmaceuticals, Inc. Earnings Call
Aug 06, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, and welcome to Tarsus Pharmaceuticals' Second Quarter 2026 Financial Results Conference Call, an announcement to acquire Alkius Pharmaceuticals. As a reminder, this call is being recorded, and all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. At this time, I would like to turn the call over to Sarah Knives, Investor Relations, to lead off the call.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Before we begin, I encourage everyone to visit the Investors section of the Tartus

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.